Lewis y/b Hapten 抗体
The 小鼠 单克隆 anti-Lewis y/b Hapten antibody (Clone SC104) (ABIN5564290) specifically detects Lewis y/b Hapten in ELISA, FACS, Func, ICC 和 IHC.
The antibody is reactive with 人 samples.
产品编号 ABIN5564290
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Lewis y/b Hapten 抗体 (ABIN5564290)
抗原
Lewis y/b Hapten
适用
人
宿主
小鼠
克隆类型
单克隆
应用范围
ELISA, Flow Cytometry (FACS), Functional Studies (Func), Immunocytochemistry (ICC), Immunohistochemistry (IHC)
克隆位点
SC104
-
-
特异性
- Recognizes human sialyltetraosylceramide. Does not bind to blood lympocytes, granulocytes, bone marrow progenitor cells, GM1, GD1a, GT1b or sialyl LewisX antigens.
-
交叉反应
- 人
-
纯度
- >95 % (SDS-PAGE)
-
内毒素水平
- <0.001EU/μg purified protein (LAL test, Lonza).
-
免疫原
- Tissue cultured colorectal tumor cell lines (C170, C146, Colo205 and JW).
-
亚型
- IgG1
-
-
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- Lot specific
-
缓冲液
- In PBS.
-
储存液
- Without preservative
-
储存条件
- 4 °C,-20 °C
-
储存方法
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C. -
有效期
- 12 months
-
-
- Lewis y/b Hapten
-
别名
- Lewisy/b hapten
-
背景
- Membrane glycolipids represent an unexplored source of tumor-associated antigens. Many of these are overexpressed and altered in tumors compared to normal tissue. Research into aberrant glycosylation and over-expression of glycolipids on the surface of the majority of cancers, coupled with a knowledge of glycolipids as functional molecules involved in a number of cellular physiological pathways, has provided a novel area of targets for cancer immunotherapy. Lewis-y/b is a cell surface carbohydrate blood group antigen expressed at very low levels in normal tissue, but often found to be overexpressed on breast, lung, colon and ovarian cancer cells. Clone SC104 recognizes a unique cell surface antigen sialyltetraosylceramide, expressed by 90 % of colorectal tumors at all clinical stages. SC104 targets colorectal cancer-associated glycolipids and induces tumor cell death in vitro independently of CDC or ADCC or blockade of known survival signaling pathways. It induces apoptotic cell death and synergizes with chemotherapy in vivo in mice.
抗原
-
You are here:
